LianBio ADR
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $1.71
- Today's High:
- $1.7877
- Open Price:
- $1.7789
- 52W Low:
- $1.07
- 52W High:
- $2.9
- Prev. Close:
- $1.72
- Volume:
- 7865
Company Statistics
- Market Cap.:
- $195.05 million
- Book Value:
- 2.069
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -20.14%
- Return on Equity TTM:
- -29.51%
Company Profile
LianBio ADR had its IPO on 2021-11-01 under the ticker symbol LIAN.
The company operates in the Healthcare sector and Biotechnology industry. LianBio ADR has a staff strength of 163 employees.
Stock update
Shares of LianBio ADR opened at $1.78 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $1.71 - $1.79, and closed at $1.77.
This is a +2.91% increase from the previous day's closing price.
A total volume of 7,865 shares were traded at the close of the day’s session.
In the last one week, shares of LianBio ADR have slipped by -2.75%.
LianBio ADR's Key Ratios
LianBio ADR has a market cap of $195.05 million, indicating a price to book ratio of 0.5401 and a price to sales ratio of 0.
In the last 12-months LianBio ADR’s revenue was $0 with a gross profit of $0 and an EBITDA of $-103552000. The EBITDA ratio measures LianBio ADR's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, LianBio ADR’s operating margin was 0% while its return on assets stood at -20.14% with a return of equity of -29.51%.
In Q2, LianBio ADR’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
LianBio ADR’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-0.82 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into LianBio ADR’s profitability.
LianBio ADR stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 1.3709. Its price to sales ratio in the trailing 12-months stood at 0.
LianBio ADR stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $278.80 million
- Total Liabilities
- $21.64 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $50000
- Dividend Payout Ratio
- 0%
LianBio ADR ended 2024 with $278.80 million in total assets and $0 in total liabilities. Its intangible assets were valued at $278.80 million while shareholder equity stood at $221.73 million.
LianBio ADR ended 2024 with $0 in deferred long-term liabilities, $21.64 million in other current liabilities, 2000.00 in common stock, $-516191000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $104.06 million and cash and short-term investments were $267.27 million. The company’s total short-term debt was $1,859,000 while long-term debt stood at $0.
LianBio ADR’s total current assets stands at $273.10 million while long-term investments were $0 and short-term investments were $163.21 million. Its net receivables were $1.03 million compared to accounts payable of $1.91 million and inventory worth $0.
In 2024, LianBio ADR's operating cash flow was $0 while its capital expenditure stood at $50000.
Comparatively, LianBio ADR paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $1.77
- 52-Week High
- $2.9
- 52-Week Low
- $1.07
- Analyst Target Price
- $7.78
LianBio ADR stock is currently trading at $1.77 per share. It touched a 52-week high of $2.9 and a 52-week low of $2.9. Analysts tracking the stock have a 12-month average target price of $7.78.
Its 50-day moving average was $2 and 200-day moving average was $2.05 The short ratio stood at 0.38 indicating a short percent outstanding of 0%.
Around 592.5% of the company’s stock are held by insiders while 7546% are held by institutions.
Frequently Asked Questions About LianBio ADR
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn’s disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.